Beclomethasone/cyclodextrin inclusion complex for dry powder inhalation

S.T.P. Pharma Sciences

Volumn 9, Issue 3, 1999, Pages 253-256

  Leite Pinto, J M C ^a   Cabral Marques, H M ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Anti asthmatic drug; Cyclodextrins; Dry powder inhalers; Inclusion complexes; Pulmonary delivery; Twin impinger

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; FREEZE DRYING; IN VITRO STUDY; INHALATION; POWDER INHALER; ROENTGEN SPECTROSCOPY; X RAY POWDER DIFFRACTION;

EID: 0345535636     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. OGDEN J., ROGERSON C. and SMITH I. - Issues in pulmonary delivery. - Scrip Mag., June, 56, 1996.
2. CABRAL MARQUES H.M. - Structure and properties of cyclodextrins. Inclusion complex formation. - Rev. Port. Farm., 44, 77-84, 1994.
3. WALL D.A., MARCELLO J., PIERDOMENICO D. and FARID A. - Administration as hydroxypropyl-β-cyclodextrin complexes does not slow rates of pulmonary drug absorption in rat. - STP Pharma Sci., 4 (1), 63-68, 1994.
4. WORTH G.M., THOMAS M., FARR S.J. and TAYLOR G. -Steroid cyclodextrin complexes for pulmonary delivery. - Proc. Int. Symp. Control. Rel. Bioact. Mater., 24, 747-748, 1997.
5. HIGUCHI T. and CONNORS K. A. - Phase solubility studies. -Adv. Anal. Chem. Instrum., 4, 117-212, 1965.
6. UEKAMA K., FUJINAGA F., HIRAYAMA F., OTAGIRI M. and YAMASAKI M. - Inclusion complexations of steroid hormones with cyclodextrins in water and in solid phase. - Int. J. Pharm., 10, 1-15, 1982.
7. CABRAL MARQUES H.M. - Preparation of complexes. Evidence for complex formation. - Rev. Port. Farm., 44 (4), 157-163, 1994.
8. CHEUNG B.W.Y., WANG Y., BREWSTER M.E. and SAWCHUK R.J. - Brain delivery of carbamazepine during intravenous administration of polyethylene glycol and 2-hydroxypropyl-β-cyclodextrin formulations. - S.T.P. Pharma Sciences, 7 (1), 78-84, 1997.